SRRK News and Press, Scholar Rock Holding Corporation From 11/07/23

Completed enrollment for pivotal Phase 3 SAPPHIRE trial evaluating apitegromab; topline data expected in 4Q 2024 Expanding into cardiometabolic disorders with SRK-439, a novel investigational myostatin inhibitor Presented new data supporting proof of concept for SRK-181 in heavily...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Scholar Rock Holding Corporation (SRRK) is expected to report $-0.53 for Q3 2023

Promising anti-tumor activity in heavily pretreated clear cell renal cell carcinoma (ccRCC) patients Objective response rate (ORR) of 21.4% and disease control rate of 57% Biomarker data supports proof of mechanism across multiple tumor types Combination therapy of SRK-181...

2023-10-25 17:44:30 ET Summary The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed enrollment and is expected to report results in Q4 2024. Data from the TOPAZ study showed consistent gains i...

Scholar Rock Holding Corporation (NASDAQ: SRRK) is one of today's top gainers. The company's shares are currently up 18.67% on the day to $9.09. Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious dis...

2023-10-25 10:00:16 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...

2023-10-24 17:37:02 ET Gainers: Vitru  ( VTRU ) +15% . Scholar Rock Holding  ( SRRK ) +7% . LianBio ( LIAN ) +5% . 908 Devices  ( MASS ) +5% . Microsoft Corporation ( MSFT ) +4% . Losers: Forbion European A...

2023-10-24 17:09:13 ET More on Scholar Rock Scholar Rock: The Market Isn't Enthusiastic Despite Decent Clinical Data Scholar Rock prices upsized $85M offering Scholar Rock plans for $75M stock offering Seeking Alpha’s Quant Rating on Scholar Rock ...

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2023 financial results an...